US EditionPublished • loading... • Updated
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues – Ortho Spine News
Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, c…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues – Ortho Spine News
Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, c…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
